Literature DB >> 21087395

Radical prostatectomy for cT3-4 disease: an evaluation of the pathological outcomes and patterns of care for adjuvant radiation in a national cohort.

David Schreiber1, Justin Rineer, Sonal Sura, Ervin Teper, Tom Nabhani, Peter Han, David Schwartz, Kwang Choi, Marvin Rotman.   

Abstract

OBJECTIVE: • To use the Surveillance, Epidemiology and End Results Database to evaluate the pathological outcomes for patients with clinically staged T3-4 disease who undergo radical prostatectomy and to analyze whether these patients are receiving adjuvant radiation. PATIENTS AND METHODS: • We identified patients who were clinically staged as having T3-4N0M0 prostate cancer and underwent radical prostatectomy between 2004 and 2006. Clinical data regarding preoperative prostate-specific antigen, as well as pathological Gleason score, were also collected. • Descriptive analyses were performed regarding the pathological extent of disease for these patients. • Logistic regression analysis was performed to identify unadjusted and adjusted predictors of radiation use for those with non-organ-confined disease or positive margins.
RESULTS: • A total of 718 patients were identified. Of these, 10.2% had organ-confined disease (8.1% with negative margins and 2.1% with positive margins). The median number of lymph nodes removed was three, with 9.9% of patients having pathologically positive lymph nodes. • The clinical accuracy of staging was found to be 81.4% for T3a, 77.4% for T3b and 70.1% for T4. Of those who had non-organ-confined disease or positive margins pathologically, 21.1% received adjuvant radiation. Logistic regression analysis revealed that those with Gleason 8-10 disease were most likely to receive adjuvant radiation.
CONCLUSIONS: • In this large series from a population-based cohort, clinical staging of T3-T4 disease was highly accurate in predicting pathological extent, with only 10.2% of patients found to have pathological T2 disease. • Most patients with confirmed pathological T3-T4 disease did not receive adjuvant radiation.
© 2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21087395     DOI: 10.1111/j.1464-410X.2010.09875.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  3 in total

1.  Long-term oncological outcome in men with T3 prostate cancer: radical prostatectomy versus external-beam radiation therapy at a single institution.

Authors:  Shinya Yamamoto; Satoru Kawakami; Junji Yonese; Yasuhisa Fujii; Shinji Urakami; Shinichi Kitsukawa; Hitoshi Masuda; Yuichi Ishikawa; Takuyo Kozuka; Masahiko Oguchi; Atsushi Kohno; Iwao Fukui
Journal:  Int J Clin Oncol       Date:  2013-12-19       Impact factor: 3.402

2.  Is More Always Better? An Assessment of the Impact of Lymph Node Yield on Outcome for Clinically Localized Prostate Cancer with Low/Intermediate Risk Pathology (pT2-3a/pN0) Managed with Prostatectomy Alone.

Authors:  Steven N Seyedin; Darrion L Mitchell; Sarah L Mott; J Kyle Russo; Chad R Tracy; Anthony N Snow; Jessica R Parkhurst; Mark C Smith; John M Buatti; John M Watkins
Journal:  Pathol Oncol Res       Date:  2017-10-27       Impact factor: 3.201

3.  Clinically high-risk prostate cancer patients comprise a relevant number of cancers with overall favorable tumor characteristics.

Authors:  M Musch; J Pluemer; U Roggenbuck; V Klevecka; D Kroepfl
Journal:  World J Urol       Date:  2014-03-26       Impact factor: 4.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.